Lingotto Investment Management LLP
+23.90%
3個月報酬率
$64.720
-5.831 (-9.01%)收盤時
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
Tempus AI Inc is currently a hold. The stock is priced at $70.93, which is below the average analyst price target of $75 from BofA and $92 from Guggenheim, indicating potential upside. However, the RSI is at 38.335, suggesting that the stock is nearing oversold conditions but still lacks strong momentum. The recent insider selling, with executives selling shares, raises concerns about confidence in the short-term performance, especially with a 5-day change of -7.44%.

Ambry Genetics Launches Comprehensive Whole Genome Sequencing Solutions

Tempus Expands Collaboration with Moderna and Merck for Intismeran Autogene

MindWalk Appoints New Director to Enhance Governance

MindWalk Appoints New Director to Enhance Governance

Tempus AI to Present 13 Studies at ESMO Congress
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. It operates in the Healthcare sector.
Tempus AI Inc is currently a hold. The stock is priced at $70.93, which is below the average analyst price target of $75 from BofA and $92 from Guggenheim, indicating potential upside. However, the RSI is at 38.335, suggesting that the stock is nearing oversold conditions but still lacks strong momentum. The recent insider selling, with executives selling shares, raises concerns about confidence in the short-term performance, especially with a 5-day change of -7.44%.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。